Welcome to our dedicated page for Agape Atp SEC filings (Ticker: atpc), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Agape Atp's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Agape Atp's regulatory disclosures and financial reporting.
Agape ATP Corporation reported that Nasdaq has confirmed the company has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company had previously received Nasdaq notices in January and February 2026 citing a bid price below $1.00 per share and a closing bid of $0.10 or less for ten consecutive trading days under the “Low Priced Stocks” rule.
Following the March 10, 2026 letter from the Nasdaq Hearings Advisor, the scheduled March 17, 2026 hearing has been cancelled, and the company’s common stock will continue trading on Nasdaq under the symbol ATPC.
Agape ATP Corporation, through its wholly owned subsidiary ATPC Green Energy Sdn. Bhd., has entered into a non-exclusive Collaboration Agreement with Citadel Investment LLC, a Dubai-based investment and global commodities trading firm, effective March 2026.
The parties plan to cooperate on the sale and purchase of oil, gas, refinery and petrochemical products by leveraging their respective commercial networks to identify, structure and facilitate cross-border energy transactions. The agreement outlines commission or profit-sharing for transactions introduced under the partnership and includes provisions on intellectual property, assignment, confidentiality, and protection of clients and business partners introduced by either party.
Agape ATP Corporation has filed a mixed shelf registration that allows it to offer and sell up to $200,000,000 of common stock, preferred stock, warrants and units over time. Actual terms, prices and amounts for each sale will be set in future prospectus supplements.
The company plans to use any proceeds for general corporate purposes, including marketing and e‑commerce for its health and wellness products, R&D and technology development, expansion into ASEAN and U.S. markets, strategic acquisitions in the wellness ecosystem, and working capital.
Agape operates primarily in Malaysia’s health and wellness sector through a direct-selling model, offering nutritional programs and complementary therapies, and is also developing renewable energy and digital wellness platforms. Its common stock trades on Nasdaq under the symbol ATPC.
Agape ATP Corporation is implementing a 1-for-50 reverse stock split of its issued and outstanding common stock. Shareholders approved an amendment allowing one or more reverse splits of up to 1-for-5,000, and the board has chosen a 1-for-50 ratio.
The reverse split is expected to become effective on February 9, 2026, with the common stock trading on a split-adjusted basis on the Nasdaq Capital Market beginning February 10, 2026, under the same symbol “ATPC.” No fractional shares will be issued; any fraction will be rounded up to the nearest whole share, and the authorised common share count will remain unchanged.
Following the reverse split, the common stock will receive a new CUSIP number, 008389306, and outstanding equity awards will be proportionately adjusted for both share amounts and exercise prices.
Agape ATP Corporation has received a determination from Nasdaq staff to delist its securities after a prolonged share price decline. The decision follows an earlier notice that the company failed to meet Nasdaq’s minimum bid price requirement of $1.00 per share.
Nasdaq staff cited that, as of January 30, 2026, Agape ATP’s securities had a closing bid of $0.10 or less for ten consecutive trading days, triggering Nasdaq’s Low Priced Stocks rule. The company plans to request a hearing by February 9, 2026, which will temporarily prevent suspension and a Form 25-NSE filing while a panel reviews the case.
Agape ATP Corporation held its Annual Meeting of Stockholders on January 30, 2026, where all matters submitted to a vote were approved. One key proposal received 30,095,479 votes for, 50 against and 421 abstentions, indicating near-unanimous support.
Stockholders also elected directors including How Kok Choong, who received 29,562,792 votes for, 2,898 withheld votes and 421 abstentions, with similar strong support levels for the other board nominees.
Agape ATP Corporation reported that Nasdaq has notified the company it no longer meets the continued listing requirement to maintain a minimum bid price of $1 per share under Nasdaq Listing Rule 5550(a)(2). The notice is based on closing bid prices from December 10, 2025 to January 26, 2026.
The company has 180 calendar days, until July 27, 2026, to regain compliance. If it meets other Nasdaq Capital Market listing standards, it may qualify for an additional 180‑day period and could use measures such as a reverse stock split. Failing to regain compliance could lead to delisting. Agape ATP is evaluating options and intends to regain compliance, but there is no assurance it will succeed.
Agape ATP Corporation filed an amendment to its proxy materials for the upcoming Annual Meeting to clarify how abstentions and broker non-votes are treated and how certain proposals will be approved.
The revised language explains that broker non-votes arise when brokers lack discretionary authority and do not receive instructions, and confirms they are not counted as shares entitled to vote on non-routine matters. It also emphasizes that beneficial owners must give specific instructions if they want their street-name shares voted on non-routine items.
For Proposal 5, which seeks to amend the articles of incorporation to increase authorized common shares from 500,000,000 to 30,000,000,000, a majority of all voting shares must vote “FOR,” and abstentions and broker non-votes will count as “NO” votes. For Proposal 6, approval requires a majority of shares present and entitled to vote, abstentions count as votes against, and the item is considered routine, so broker non-votes are not expected.
Agape ATP Corporation is asking stockholders to approve several major corporate actions at its virtual annual meeting on January 30, 2026. Holders of 50,027,000 common shares as of November 4, 2025 can vote on ratifying Assentsure PAC as auditor, re-electing five directors, and authorizing potential issuances of common stock with an aggregate offering price of up to $300,000,000 under a future Form S-3 shelf. The company is also seeking authority for the board to implement one or more reverse stock splits of up to 1-for-5,000 and to increase authorized common shares from 500,000,000 to 30,000,000,000, which could significantly expand its ability to issue new equity. Another proposal would allow adjournment of the meeting to solicit more proxies if needed.
Agape ATP Corporation issued a press release on December 12, 2025 titled “Agape ATP Corporation Issues Statement on Recent Market Activity and Reaffirms Strategic Outlook.” The company furnished this press release as Exhibit 99.1 to a current report so readers can review its statement on recent market conditions and its reaffirmed strategic plans.